SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-021642
Filing Date
2023-06-16
Accepted
2023-06-16 16:01:37
Documents
14
Period of Report
2023-06-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 38913
2 ex99-1.htm EX-99.1 51310
3 ex99-1_001.jpg GRAPHIC 5955
  Complete submission text file 0001493152-23-021642.txt   280103

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE evfm-20230616.xsd EX-101.SCH 2953
5 XBRL LABEL FILE evfm-20230616_lab.xml EX-101.LAB 34916
6 XBRL PRESENTATION FILE evfm-20230616_pre.xml EX-101.PRE 22785
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3673
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

IRS No.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 231020860
SIC: 2834 Pharmaceutical Preparations